Generic name: interferon beta-1a
Dosage form: injection, solution
This dosage information does not include all the information needed to use Rebif safely and effectively. See full prescribing information for Rebif.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Dosages of Rebif® shown to be safe and effective are 22 mcg and 44 mcg injected subcutaneously three times per week. Rebif® should be administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days (e.g., Monday, Wednesday, and Friday) at least 48 hours apart each week (see CLINICAL STUDIES). Generally, patients should be started at 20% of the prescribed dose three times per week and increased over a 4-week period to the targeted dose, either 22 mcg three times per week (see Table 4) or 44 mcg three times per week (see Table 5). Patients prescribed a targeted dose of 22 mcg three times per week should use the pre-filled syringes for titration. Following the administration of each dose, any residual product remaining in the syringe should be discarded in a safe and proper manner.
A Titration Pack containing 6 doses of 8.8 mcg (0.2 mL) and 6 doses of 22 mcg (0.5 mL) is available for use during the titration period in both Rebif® pre-filled syringes and Rebif® Rebidose® autoinjectors.
|Week of Use||Dose||Syringe to Use||Amount of syringe|
|Week 1 Titration||4.4 mcg||8.8 mcg syringe||Use half of syringe|
|Week 2 Titration||4.4 mcg||8.8 mcg syringe||Use half of syringe|
|Week 3 Titration||11 mcg||22 mcg syringe||Use half of syringe|
|Week 4 Titration||11.mcg||22 mcg syringe||Use half of syringe|
|Week 5 and on||22 mcg||22 mcg syringe or autoinjector||Use full syringe or autoinjector|
|Week of Use||Dose||Syringe or Autoinjector to Use||Amount of syringe or autoinjector|
|Week 1 Titration||8.8 mcg||8.8 mcg syringe or autoinjector||Use full syringe or autoinjector|
|Week 2 Titration||8.8 mcg||8.8 mcg syringe or autoinjector||Use full syringe or autoinjector|
|Week 3 Titration||22 mcg||22 mcg syringe or autoinjector||Use full syringe or autoinjector|
|Week 4 Titration||22 mcg||22 mcg syringe or autoinjector||Use full syringe or autoinjector|
|Week 5 and on||44 mcg||44 mcg syringe or autoinjector||Use full syringe or autoinjector|
Leukopenia or elevated liver function tests may necessitate dose reduction or discontinuation of Rebif® administration until toxicity is resolved (see WARNINGS: Hepatic Injury, PRECAUTIONS: General and ADVERSE REACTIONS).
Rebif® is intended for use under the guidance and supervision of a physician. It is recommended that physicians or qualified medical personnel train patients in the proper technique for self-administering subcutaneous (sc) injections using the pre-filled syringe or injection device approved for use with Rebif®. Injection depth of the Rebif® Rebidose® autoinjector is fixed at 8 mm; the health care provider should determine the injection technique. Patients should be advised to rotate sites for sc injections (see PRECAUTIONS: Information for Patients). Concurrent use of analgesics and/or antipyretics may help ameliorate flu-like symptoms on treatment days. Rebif® should be inspected visually for particulate matter and discoloration prior to administration.